哮喘中性粒细胞炎症与上皮翻译控制缺陷
研究探讨哮喘患者原代支气管上皮细胞(PBEC)对IL-17A和TNF-α刺激产生CXCL-8的反应,发现多数患者PBEC存在过度产生且对糖皮质激素不敏感,该高反应性与BALF中CXCL-8水平和中性粒细胞数及支气管舒张剂诱导的FEV1逆转率相关,机制涉及TiAR胞质转位失败。
要点
- 哮喘患者PBEC对IL-17A联合TNF-α的CXCL-8高反应性与气道中性粒细胞炎症相关。
- 该上皮高反应性对糖皮质激素不敏感,且与支气管舒张剂诱导的FEV1逆转率相关。
- TiAR胞质转位失败导致CXCL-8翻译去抑制,是潜在治疗靶点。
核心结论
- 哮喘患者高反应性PBEC可能介导中性粒细胞性和糖皮质激素不敏感炎症及FEV1降低,独立于嗜酸性炎症。
- 恢复正常TiAR胞质转位是中性粒细胞性、糖皮质激素不敏感哮喘的潜在治疗靶点。
研究设计与样本
- 研究对比哮喘患者与对照的PBEC,检测TNF-α和IL-17A刺激下CXCL-8产生。
- 分析PBEC反应性与BALF中CXCL-8水平、中性粒细胞数、嗜酸性粒细胞数及FEV1逆转率的相关性。
- 通过TiAR敲低验证其在CXCL-8翻译控制中的作用。
主要发现
- 多数哮喘患者PBEC对TNF-α和IL-17A联合刺激产生过量CXCL-8,但对TNF-α单独刺激无此反应,且对糖皮质激素不敏感。
- PBEC高反应性与BALF中CXCL-8水平和中性粒细胞数强烈相关,但与嗜酸性粒细胞数不相关。
- PBEC高反应性也与支气管舒张剂诱导的FEV1%逆转率相关。
- 上皮高反应性与TiAR未能转位至胞质以终止CXCL-8产生相关,TiAR敲低证实此机制。
- 高反应性PBEC还产生其他炎症介质增强水平。
临床怎么用
- PBEC对IL-17A联合TNF-α的CXCL-8反应性可用于识别中性粒细胞性、糖皮质激素不敏感哮喘患者。
- 针对TiAR胞质转位的干预可能成为此类哮喘的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neutrophilic inflammation in asthma is associated with interleukin (IL)-17A, corticosteroid-insensitivity and bronchodilator-induced forced expiratory volume in 1 s (FEV1) reversibility. IL-17A synergises with tumour necrosis factor (TNF)-α in the production of the neutrophil chemokine CXCL-8 by primary bronchial epithelial cells (PBECs).We hypothesised that local neutrophilic inflammation in asthma correlates with IL-17A and TNF-α-induced CXCL-8 production by PBECs from asthma patients.PBECs from most asthma patients displayed an exaggerated CXCL-8 production in response to TNF-α and IL-17A, but not to TNF-α alone, and which was also insensitive to corticosteroids. This hyperresponsiveness of PBECs strongly correlated with CXCL-8 levels and neutrophil numbers in bronchoalveolar lavage from the corresponding patients, but not with that of eosinophils. In addition, this hyperresponsiveness also correlated with bronchodilator-induced FEV1 % reversibility. At the molecular level, epithelial hyperresponsiveness was associated with failure of the translational repressor T-cell internal antigen-1 related protein (TiAR) to translocate to the cytoplasm to halt CXCL-8 production, as confirmed by TiAR knockdown. This is in line with the finding that hyperresponsive PBECs also produced enhanced levels of other inflammatory mediators.Hyperresponsive PBECs in asthma patients may underlie neutrophilic and corticosteroid-insensitive inflammation and a reduced FEV1, irrespective of eosinophilic inflammation. Normalising cytoplasmic translocation of TiAR is a potential therapeutic target in neutrophilic, corticosteroid-insensitive asthma.
引用
- Ravi A, Chowdhury S, Dijkhuis A, et al. Neutrophilic inflammation in asthma and defective epithelial translational control. Eur Respir J. 2019. PMID: 31109984. doi:10.1183/13993003.00547-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。